Loading...
Loading...
India's paclitaxel imports from SOUTH KOREA total $1.6B across 27 shipments from 1 foreign suppliers. SAMYANG HOLDINGS CORPORATION leads with $1.6B in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include LUPIN LIMITED. This corridor reflects India's pharmaceutical import demand for paclitaxel — a concentrated sourcing relationship with select suppliers from SOUTH KOREA.

SAMYANG HOLDINGS CORPORATION is the leading Paclitaxel supplier from SOUTH KOREA to India, with import value of $1.6B across 27 shipments. The top 5 suppliers — SAMYANG HOLDINGS CORPORATION — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SAMYANG HOLDINGS CORPORATION | $1.6B | 27 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | LUPIN LIMITED | $1.6B | 25 | 100.0% |
| 2 | LUPIN LTD | $80.7K | 1 | 0.0% |
| 3 | SAHAJANAND MEDICAL TECHNOLOGIES PVT LTD | $12.5K | 1 | 0.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Paclitaxel suppliers from SOUTH KOREA to India include SAMYANG HOLDINGS CORPORATION. The leading supplier is SAMYANG HOLDINGS CORPORATION with import value of $1.6B USD across 27 shipments. India imported Paclitaxel worth $1.6B USD from SOUTH KOREA in total across 27 shipments.
India imported Paclitaxel worth $1.6B USD from SOUTH KOREA across 27 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Paclitaxel sourced from SOUTH KOREA include LUPIN LIMITED, LUPIN LTD, SAHAJANAND MEDICAL TECHNOLOGIES PVT LTD. The largest buyer is LUPIN LIMITED with $1.6B in imports across 25 shipments.
The total value of Paclitaxel imports from SOUTH KOREA to India is $1.6B USD, across 27 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
27 Verified Shipments
1 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists